Related Experiment Video

Updated: Apr 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.1K

[Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)]

Hideyuki Akaza

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |December 19, 2014
    PubMed

    Insights

    Japan

    Area of Science:

    • Oncology
    • Urology
    • Medical Treatments

    Context:

    • Recent approvals of novel agents for castration-resistant prostate cancer (CRPC) in Japan mark a significant advancement.
    • Treatment options for CRPC in Japan lagged Western introductions by 2-3 years.
    • A successful Phase III trial of chemo-hormonal therapy for hormone-naive metastatic prostate cancer (HRPC) was presented at ASCO 2014.

    Purpose:

    • To discuss the evolving treatment landscape for advanced and high-risk prostate cancer in Japan.
    • To highlight the implications of new drug approvals and clinical trial results.
    • To advocate for the establishment of optimized treatment strategies.

    Summary:

    • New agents for castration-resistant prostate cancer (CRPC) are now available in Japan.
    • A Phase III trial demonstrated the efficacy of chemo-hormonal therapy for hormone-naive metastatic prostate cancer (HRPC).
    • These developments necessitate a re-evaluation of treatment strategies for advanced prostate cancer.

    Impact:

    • Accelerated adoption of advanced prostate cancer therapies in Japan.
    • Improved treatment paradigms for both hormone-naive and castration-resistant prostate cancer.
    • Potential for enhanced patient outcomes through evidence-based treatment selection.

    More Related Videos

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.1K
    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

    Published on: November 19, 2019

    7.3K

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    1.8K
    Disorders of the Male Reproductive System01:20

    Disorders of the Male Reproductive System

    Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
    Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
    5.6K